Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness.

Bencsikova B, Budinska E, Selingerova I, Pilatova K, Fedorova L, Greplova K, Nenutil R, Valik D, Obermannova R, Sheard MA, Zdrazilova-Dubska L.

BMC Cancer. 2019 Jul 15;19(1):687. doi: 10.1186/s12885-019-5909-5.

2.

Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells.

Wu HW, Sheard MA, Malvar J, Fernandez GE, DeClerck YA, Blavier L, Shimada H, Theuer CP, Sposto R, Seeger RC.

Clin Cancer Res. 2019 Aug 1;25(15):4761-4774. doi: 10.1158/1078-0432.CCR-18-3358. Epub 2019 May 8.

3.

Activated Natural Killer Cells in Combination with Anti-GD2 Antibody Dinutuximab Improve Survival of Mice after Surgical Resection of Primary Neuroblastoma.

Barry WE, Jackson JR, Asuelime GE, Wu HW, Sun J, Wan Z, Malvar J, Sheard MA, Wang L, Seeger RC, Kim ES.

Clin Cancer Res. 2019 Jan 1;25(1):325-333. doi: 10.1158/1078-0432.CCR-18-1317. Epub 2018 Sep 19.

4.

Colony stimulating factor 1 receptor blockade improves the efficacy of chemotherapy against human neuroblastoma in the absence of T lymphocytes.

Webb MW, Sun J, Sheard MA, Liu WY, Wu HW, Jackson JR, Malvar J, Sposto R, Daniel D, Seeger RC.

Int J Cancer. 2018 Sep 15;143(6):1483-1493. doi: 10.1002/ijc.31532. Epub 2018 May 7.

5.

Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors.

Robison NJ, Yeo KK, Berliner AP, Malvar J, Sheard MA, Margol AS, Seeger RC, Rushing T, Finlay JL, Sposto R, Dhall G.

J Neurooncol. 2018 May;138(1):199-207. doi: 10.1007/s11060-018-2791-y. Epub 2018 Feb 9.

6.

Tumor-associated macrophages promote neuroblastoma via STAT3 phosphorylation and up-regulation of c-MYC.

Hadjidaniel MD, Muthugounder S, Hung LT, Sheard MA, Shirinbak S, Chan RY, Nakata R, Borriello L, Malvar J, Kennedy RJ, Iwakura H, Akamizu T, Sposto R, Shimada H, DeClerck YA, Asgharzadeh S.

Oncotarget. 2017 Sep 16;8(53):91516-91529. doi: 10.18632/oncotarget.21066. eCollection 2017 Oct 31.

7.

Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells.

Borriello L, Nakata R, Sheard MA, Fernandez GE, Sposto R, Malvar J, Blavier L, Shimada H, Asgharzadeh S, Seeger RC, DeClerck YA.

Cancer Res. 2017 Sep 15;77(18):5142-5157. doi: 10.1158/0008-5472.CAN-16-2586. Epub 2017 Jul 7.

8.

TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.

Tran HC, Wan Z, Sheard MA, Sun J, Jackson JR, Malvar J, Xu Y, Wang L, Sposto R, Kim ES, Asgharzadeh S, Seeger RC.

Clin Cancer Res. 2017 Feb 1;23(3):804-813. doi: 10.1158/1078-0432.CCR-16-1743. Epub 2016 Oct 10.

9.

Preservation of high glycolytic phenotype by establishing new acute lymphoblastic leukemia cell lines at physiologic oxygen concentration.

Sheard MA, Ghent MV, Cabral DJ, Lee JC, Khankaldyyan V, Ji L, Wu SQ, Kang MH, Sposto R, Asgharzadeh S, Reynolds CP.

Exp Cell Res. 2015 May 15;334(1):78-89. doi: 10.1016/j.yexcr.2015.03.024. Epub 2015 Apr 3.

PMID:
25845499
10.

Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1.

Xu Y, Sun J, Sheard MA, Tran HC, Wan Z, Liu WY, Asgharzadeh S, Sposto R, Wu HW, Seeger RC.

Cancer Immunol Immunother. 2013 Oct;62(10):1637-48. doi: 10.1007/s00262-013-1466-y. Epub 2013 Aug 27.

11.

Membrane-bound TRAIL supplements natural killer cell cytotoxicity against neuroblastoma cells.

Sheard MA, Asgharzadeh S, Liu Y, Lin TY, Wu HW, Ji L, Groshen S, Lee DA, Seeger RC.

J Immunother. 2013 Jun;36(5):319-29. doi: 10.1097/CJI.0b013e31829b4493.

12.

Critical role of STAT3 in IL-6-mediated drug resistance in human neuroblastoma.

Ara T, Nakata R, Sheard MA, Shimada H, Buettner R, Groshen SG, Ji L, Yu H, Jove R, Seeger RC, DeClerck YA.

Cancer Res. 2013 Jul 1;73(13):3852-64. doi: 10.1158/0008-5472.CAN-12-2353. Epub 2013 Apr 30.

13.

Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy.

Liu Y, Wu HW, Sheard MA, Sposto R, Somanchi SS, Cooper LJ, Lee DA, Seeger RC.

Clin Cancer Res. 2013 Apr 15;19(8):2132-43. doi: 10.1158/1078-0432.CCR-12-1243. Epub 2013 Feb 1.

14.

Meningitic Escherichia coli K1 penetration and neutrophil transmigration across the blood-brain barrier are modulated by alpha7 nicotinic receptor.

Chi F, Wang L, Zheng X, Wu CH, Jong A, Sheard MA, Shi W, Huang SH.

PLoS One. 2011;6(9):e25016. doi: 10.1371/journal.pone.0025016. Epub 2011 Sep 22.

15.

Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53.

Huang JM, Sheard MA, Ji L, Sposto R, Keshelava N.

Mol Cancer Ther. 2010 Dec;9(12):3289-301. doi: 10.1158/1535-7163.MCT-10-0562.

16.

Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo.

Kang MH, Kang YH, Szymanska B, Wilczynska-Kalak U, Sheard MA, Harned TM, Lock RB, Reynolds CP.

Blood. 2007 Sep 15;110(6):2057-66. Epub 2007 May 29.

PMID:
17536015
17.
18.

Dimethyl sulfoxide potentiates death receptor-mediated apoptosis in the human myeloid leukemia U937 cell line through enhancement of mitochondrial membrane depolarization.

Vondrácek J, Soucek K, Sheard MA, Chramostová K, Andrysík Z, Hofmanová J, Kozubík A.

Leuk Res. 2006 Jan;30(1):81-9. Epub 2005 Jul 5.

PMID:
15998540
19.

Developmental status of CD4-CD8+ and CD4+CD8- thymocytes with medium expression of CD3.

Sheard MA, Liu C, Takahama Y.

Eur J Immunol. 2004 Jan;34(1):25-35.

20.
21.

Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis.

Sheard MA, Vojtesek B, Simickova M, Valik D.

J Cell Biochem. 2002;85(4):670-7.

PMID:
11968007
22.
23.

Ionizing radiation as a response-enhancing agent for CD95-mediated apoptosis.

Sheard MA.

Int J Cancer. 2001 Aug 20;96(4):213-20. Review.

24.

Modulation of death receptor-mediated apoptosis in differentiating human myeloid leukemia HL-60 cells.

Vondrácek J, Sheard MA, Krejcí P, Minksová K, Hofmanová J, Kozubík A.

J Leukoc Biol. 2001 May;69(5):794-802.

PMID:
11358989
25.
26.

Cells in the spotlight of cancer research.

Sheard MA.

Folia Biol (Praha). 1998;44(6):221-3. No abstract available.

PMID:
10730867
27.
28.

A mathematical model for bacterial inactivation.

Xiong R, Xie G, Edmondson AE, Sheard MA.

Int J Food Microbiol. 1999 Jan 12;46(1):45-55.

PMID:
10050684
29.

Up-regulation of Fas (CD95) in human p53wild-type cancer cells treated with ionizing radiation.

Sheard MA, Vojtesek B, Janakova L, Kovarik J, Zaloudik J.

Int J Cancer. 1997 Nov 27;73(5):757-62.

30.
31.
32.
34.

Intermittent vs maintenance medication in schizophrenia. Two-year results.

Herz MI, Glazer WM, Mostert MA, Sheard MA, Szymanski HV, Hafez H, Mirza M, Vana J.

Arch Gen Psychiatry. 1991 Apr;48(4):333-9.

PMID:
1672588
35.

Phenotypic characterization of murine tumor-infiltrating T lymphocytes.

Karpati RM, Banks SM, Malissen B, Rosenberg SA, Sheard MA, Weber JS, Hodes RJ.

J Immunol. 1991 Mar 15;146(6):2043-51.

PMID:
1672340

Supplemental Content

Loading ...
Support Center